• Cempra Inc., of Chapel Hill, N.C., said the Biomedical Advanced Research and Development Authority (BARDA) awarded the company a five-year contract valued at up to $58 million for the development of solithromycin to treat infections in pediatric populations and for the treatment of infections by bioterror threat pathogens.